Banner
Identification
Name Rasburicase
Accession Number DB00049 (BIOD00090, BTD00090)
Type biotech
Groups approved
Description

Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Protein structure Db00049
Display: 3D Structure
Protein chemical formula C1521H2381N417O461S7
Protein average weight 34109.5000
Sequences 
>DB00049 sequence
SAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKADNSVIVATDSI
KNTIYITAKQNPVTPPELFGSILGTHFIEKYNHIHAAHVNIVCHRWTRMDIDGKPHPHSF
IRDSEEKRNVQVDVVEGKGIDIKSSLSGLTVLKSTNSQFWGFLRDEYTTLKETWDRILST
DVDATWQWKNFSGLQEVRSHVPKFDATWATAREVTLKTFAEDNSASVQATMYKMAEQILA
RQQLIETVEYSLPNKHYFEIDLSWHKGLQNTGKNAEVFAPQSDPNGLIKCTVGRSSLKSK
L

FASTA
Synonyms
Urate oxidase
Uricase
Salts Not Available
Brand names
Name Company
Elitek
Elitek (Sanofi-Synthelabo Inc)
Fasturtec
Brand mixtures Not Available
Categories
  • Antihyperuricemic Agents
CAS number 134774-45-1
Taxonomy
Kingdom Not Available
Classes Not Available
Substructures Not Available
Pharmacology
Indication For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)
Pharmacodynamics Drugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of action Rasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
Absorption Not Available
Volume of distribution
  • 110 to 127 mL/kg [pediatric patients]
  • 75.8 to 138 mL/kg [adult patients]
Protein binding Not Available
Metabolism
Not Available
Route of elimination Not Available
Half life 18 hours
Clearance Not Available
Toxicity Not Available
Affected organisms
  • Humans and other mammals
Pathways Not Available
Pharmacoeconomics
Manufacturers Not Available
Packagers
Dosage forms
Form Route Strength
Powder, for solution Intravenous
Prices
Unit description Cost Unit
Elitek 7.5 mg vial 3136.18 USD vial
Elitek 1.5 mg vial 627.23 USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Country Patent Number Approved Expires (estimated)
Canada 2175971 2003-12-30 2016-05-07
Canada 2148537 2002-07-16 2015-05-03
Properties
State liquid
Experimental Properties
Property Value Source
hydrophobicity -0.465 Not Available
isoelectric point 7.16 Not Available
References
Synthesis Reference Not Available
General Reference
  1. Giraldez M: A single, fixed dose of Rasburicase (6 mg maximum) for Treatment of Tumor Lysis Syndrome in Adults. Eur J Haematol. 2010 Apr 12. Pubmed 20394650
  2. Collings I, Watier Y, Giffard M, Dagogo S, Kahn R, Bonnete F, Wright JP, Fitch AN, Margiolaki I: Polymorphism of microcrystalline urate oxidase from Aspergillus flavus. Acta Crystallogr D Biol Crystallogr. 2010 May;66(Pt 5):539-48. Epub 2010 Apr 21. Pubmed
External Links
Resource Link
UniProt Q00511 Link_out
Genbank X61766 Link_out
PharmGKB PA10176 Link_out
Drug Product Database 2248416 Link_out
RxList http://www.rxlist.com/cgi/generic3/elitek.htm Link_out
Drugs.com http://www.drugs.com/cdi/rasburicase.html Link_out
Wikipedia http://en.wikipedia.org/wiki/Rasburicase Link_out
ATC Codes
  • V03AF07
AHFS Codes
  • 44:00.00
PDB Entries
FDA label show (49.1 KB)
MSDS Not Available
Interactions
Drug Interactions Searched, but no interactions found.
Food Interactions Not Available
Targets

1. Uric acid

Pharmacological action: yes
Actions: metabolizer

References:
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Cete S, Yasar A, Arslan F: An amperometric biosensor for uric acid determination prepared from uricase immobilized in polypyrrole film. Artif Cells Blood Substit Immobil Biotechnol. 2006;34(3):367-80. Pubmed
  4. Gabison L, Chiadmi M, Colloc’h N, Castro B, El Hajji M, Prange T: Recapture of [S]-allantoin, the product of the two-step degradation of uric acid, by urate oxidase. FEBS Lett. 2006 Apr 3;580(8):2087-91. Epub 2006 Mar 10. Pubmed
  5. Zhao Y, Zhao L, Yang G, Tao J, Bu Y, Liao F: Characterization of a uricase from Bacillus fastidious A.T.C.C. 26904 and its application to serum uric acid assay by a patented kinetic uricase method. Biotechnol Appl Biochem. 2006 Sep;45(Pt 2):75-80. Pubmed
  6. Giraldez M: A single, fixed dose of Rasburicase (6 mg maximum) for Treatment of Tumor Lysis Syndrome in Adults. Eur J Haematol. 2010 Apr 12. Pubmed
Comments
Drug created on June 13, 2005 07:24 / Updated on August 07, 2011 00:47